Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/23/2021 07/26/2021 07/27/2021 07/28/2021 07/29/2021 Date
118.19(c) 117.79(c) 117.96(c) 118.55(c) 118.87(c) Last
4 411 471 3 730 133 3 773 332 5 650 734 4 623 767 Volume
+0.55% -0.34% +0.14% +0.50% +0.27% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 55 876 M - -
Net income 2021 13 834 M - -
Net Debt 2021 63 665 M - -
P/E ratio 2021 15,2x
Yield 2021 4,33%
Sales 2022 59 484 M - -
Net income 2022 15 875 M - -
Net Debt 2022 49 840 M - -
P/E ratio 2022 12,8x
Yield 2022 4,66%
Capitalization 210 B 210 B -
EV / Sales 2021 4,90x
EV / Sales 2022 4,37x
Nbr of Employees 48 000
Free-Float 98,0%
More Financials
Company
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human... 
Read more
Sector
Pharmaceuticals
Calendar
07/30Earnings Release
More about the company
Ratings of AbbVie Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ABBVIE INC.
03:49pABBVIE : Gets US FDA OK for Expanded Botox Label to Treat Adults With Upper Limb..
MT
08:31aABBVIE : FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eigh..
PR
07:03aAllergan's Botox Gets FDA OK for More Muscles in Adult Spasticity
DJ
07/27Amgen to Buy Teneobio; Deal Includes $900 Million Upfront, Potential Mileston..
DJ
07/27ABBVIE : Truist Assumes Coverage of AbbVie With Buy Rating, $118 Price Target
MT
07/27ABBVIE : Calico Extend Collaboration on Age-Related Diseases
MT
07/27ABBVIE : and Calico Announce Second Extension of Collaboration Focused on Aging ..
PR
07/27AbbVie and Calico Life Sciences Announces Second Extension of Collaboration F..
CI
07/26ABBVIE : New Data Presented on the Safety and Efficacy of Investigational AGN-19..
AQ
07/26AbbVie Eye Drug AGN-190584 Meets Endpoints in Phase 3 Study
DJ
07/26ABBVIE : Presents Favorable Safety, Efficacy Data on Treatment for Presbyopia
MT
07/23ABBVIE : Wins FDA Approval for Dalvance in Treating Acute Bacterial Skin, Skin S..
MT
07/23ABBVIE : DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial ..
PR
07/23DALVANCE (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin an..
CI
07/23AbbVie Gets FDA OK for Pediatric Skin Infection Drug
DJ
More news
News in other languages on ABBVIE INC.
11:43aTAGESVORSCHAU : Termine am 30. Juli 2021
10:26aBEURSAGENDA : buitenlandse fondsen
12:38aBEURSAGENDA : buitenlandse fondsen
07/28BEURSAGENDA : buitenlandse fondsen
07/28BEURSAGENDA : buitenlandse fondsen
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Analysis
Drugmakers, pharmacies next targets for U.S. opioid settlements
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 118,87 $
Average target price 122,99 $
Spread / Average Target 3,47%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.10.94%209 386
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
PFIZER, INC.18.04%243 220
ELI LILLY AND COMPANY46.00%224 084
NOVARTIS AG0.39%223 750